


VICTORIA HARVEY-JONES PhD, SANNEKE KOEKKOEK: Medscape, Global Education, London, United Kingdom;
MARIA-VICTORIA MATEOS MD, PhD: Professor, University Hospital of Salamanca, Salamanca, Spain

BACKGROUND

With B-cell maturation antigen (BCMA)-targeted therapies available for multiple myeloma (MM), such as for triple-class refractory disease, it is important that physicians are knowledgeable and competent in how to use these agents. This study aimed to determine whether online continuing medical education could improve the knowledge, competence, and confidence of hematologists/oncologists (hem/oncs) in managing patients with triple-class refractory MM who are candidates for BCMA-targeted therapy, using a case-based approach.




METHODS





Hem/oncs participated in a 16-minute segmented online multi-media activity consisting of videos portraying realistic physician-patient interactions followed by expert commentaries.¹ The activity launched 1 April 2022 with data collection through 16 December 2022.

How to Read the Linked Learner Assessment




RESULTS

Overall, significant improvements in hem/onc knowledge and competence were seen after participation in the education. 180% more hem/oncs answered all questions correctly after the education (15% pre, 42% post).




INCREASED KNOWLEDGE REGARDING THE PROGNOSIS OF PATIENTS WITH TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

Significant improvements in knowledge of hem/oncs regarding the prognosis of patients with triple-class refractory MM.




GREATER COMPETENCE RELATED TO SELECTING THE APPROPRIATE TREATMENT BASED ON DISEASE-RELATED FACTORS FOR PATIENTS WITH TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

Significant improvements in competence related to selecting the appropriate treatment based on disease-related factors for patients with triple-class refractory disease.



CONFIDENCE ASSESSMENT

Following participation in the education, 42% of hem/oncs had a measurable increase in confidence, resulting in 25% who were mostly or very confident in managing patients with relapsed/refractory MM who are eligible for BCMA-targeted therapy.



CONCLUSIONS

- This study demonstrates the ability of innovative online, interactive case-based models to transform access to new educational opportunities and improve knowledge and competence of hem/oncs in managing patients with triple-class refractory MM. This could lead to improvements in the management of this patient population.
- Both improvement and reinforcement in the context of a linked learning assessment have been shown to positively correlate with increases in confidence as well as intention to make clinical practice changes,² suggesting that most clinicians who participated in this activity are likely to make practice changes that may lead to improved overall outcomes for these patients.

REFERENCES

- Mateos MV. Challenges in Myeloma Treatment: The Patient With Triple-Class Refractory Disease. Launched: 1/4/2022. Data as of 16/12/2022. Available at www.medscape.org/viewarticle/971037
- Lucero KS, Chen P. What do reinforcement and confidence have to do with it? A systematic pathway analysis of knowledge, competence, confidence, and intention to change. *J Eur CME*. 2020;9:1834759.

ACKNOWLEDGEMENTS

This CPD activity was supported by an independent educational grant from GSK.

DISCLOSURES

Victoria Harvey-Jones, PhD, and Sanneke Koekkoek have disclosed no relevant financial relationships. Maria-Victoria Mateos MD, PhD, has disclosed the following relevant financial relationships: Served as a consultant or advisor for: AbbVie; Adaptive; Amgen; Bluebird; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Oncopeptides; Pfizer; Regeneron; Roche; Sanofi; Seagen, Inc., formerly Seattle Genetics, Inc.; Takeda. Served as a speaker or member of speakers bureau for: Adaptive; Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Oncopeptides; Sanofi; Takeda

For more information, contact:
Victoria Harvey-Jones, PhD,
Clinical Strategist, Medscape Oncology Global,
vharveyjones@webmd.net.



Scan here to view this poster online.